Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M. +2 more·2001·New England Journal of Medicine
DOI 10.1056/nejmoa011161

Cited by (7,499)

Items 701–800 of 7,499

  1. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
    I Guerrero Feria, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A. González, Norma Uribe, Romeo García-Torres, Fernando López‐Casillas, Gerardo Gamba, Norma Araceli Bobadilla · 2003 · Kidney International
  2. Chronic kidney disease in adults—UK guidelines for identification, management and referral
    Raymond Camille Vanholder · 2006 · Nephrology Dialysis Transplantation
  3. Regression of Glomerulosclerosis with High-Dose Angiotensin Inhibition Is Linked to Decreased Plasminogen Activator Inhibitor-1
    Lijun Ma, Shinya Nakamura, Jean‐Claude Aldigier · 2005 · Journal of the American Society of Nephrology
  4. Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England
    Herrington, William G., Smith, Margaret, Bankhead, Clare, Matsushita, Kunihiro, Stevens, Sarah, Holt, Tim, Hobbs, F. D. Richard, Coresh, Josef, Woodward, Mark · 2017 · PLOS ONE
  5. Prevention of Type 2 Diabetes and Its Complications in Developing Countries: A Review
    Lal Bahadur Rawal, Robyn Jennifer Tapp, Emily D. Williams, Carina K. Y. Chan, Shajahan Yasin, Brian F. Oldenburg · 2011 · International Journal of Behavioral Medicine
  6. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America
    Dunlay, Shannon M., Givertz, Michael M., Aguilar, David, Allen, Larry A., Chan, Michael, Desai, Akshay S., Deswal, Anita, Dickson, Victoria Vaughan, Kosiborod, Mikhail N., Lekavich, Carolyn L. et al. · 2019 · Journal of Cardiac Failure
  7. The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure
    Bakris, George L., Sica, Domenic, Weber, Michael, White, William B., Roberts, Andrew, Perez, Alfonso, Cao, Charlie, Kupfer, Stuart · 2011 · The Journal of Clinical Hypertension
  8. Renal Effects of Guideline-Directed Medical Therapies in Heart Failure: A Consensus Document from the Heart Failure Association of the European Society of Cardiology
    Wilfried Müllens, Pieter Martens, Jeffrey Moore Testani, W.H. Wilson Tang, Hadi N. Skouri, Frederik Hendrik Verbrugge, Marat Fudim, Massimo Iacoviello, Jennifer Franke, Andreas J. Flammer et al. · 2022 · European Journal of Heart Failure
  9. Management of Uncontrolled Hypertension in a Nurse-Led Clinic Compared With Conventional Care for Patients with Type 2 Diabetes
    E. Denver, Maria Barnard, Robin G. Woolfson, Kenneth Earle · 2003 · Diabetes Care
  10. Valsartan Improves Arterial Stiffness in Type 2 Diabetes Independently of Blood Pressure Lowering
    Janaka J. Karalliedde, Andrew H. Smith, Lorenita DeAngelis, Vincenzo Mirenda, Albert Kandra, Jaco Botha, Philippe C. Ferber, Giancarlo C. Viberti · 2008 · Hypertension
  11. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial
    Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W., Agarwal, Rajiv, Cannon, Christopher P., Capuano, George, Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom et al. · 2020 · Clinical Journal of the American Society of Nephrology
  12. South African hypertension guideline 2006.
    Y.K. Seedat, Croasdale Ma, Frank J. Milne, Lionel Henry Opie, Pinkney-Atkinson Vj, Brian Lindsay Rayner, Yosuf Veriava · 2006 · PubMed
  13. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study
    Rita Rachmani, Inna Slavachevsky, M Amit, Zohar Levi, Yoav Kedar, Maya Berla, Mordchai Ravid · 2004 · Diabetic Medicine · Retracted
  14. GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials
    Hiddo J.L. Heerspink, Hocine Tighiouart, Yingying Sang, Shoshana H. Ballew, Hasi Mondal, Kunihiro Matsushita, Josef Coresh, Andrew S. Levey, Lesley A. Inker · 2014 · American Journal of Kidney Diseases
  15. Proteinuria and its relation to cardiovascular disease
    Christian Delles, Gemma E. Currie · 2013 · International Journal of Nephrology and Renovascular Disease
  16. Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD
    Akshay Suvas Desai, Robert D. Toto, Petr Jarolı́m, Hajime Uno, Kai‐Uwe Eckardt, Reshma Kewalramani, Andrew S. Levey, Eldrin Foster Lewis, John J.V. McMurray, Hans‐Henrik Parving et al. · 2011 · American Journal of Kidney Diseases
  17. Importance of Blood Pressure Control in Chronic Kidney Disease
    Maura Ravera, Michela Re, Luca Deferrari, Simone Vettoretti, Giacomo Deferrari · 2006 · Journal of the American Society of Nephrology
  18. Diabetic nephropathy
    Themis Zelmanovitz, Fernando Gerchman, Amely Ps Balthazar, Fúlvio Clemo Santos Thomazelli, Jorge Dias de Matos, Luís Henrique Santos Canani · 2009 · Diabetology & Metabolic Syndrome
  19. Aldosterone Suppresses Insulin Signaling Via the Downregulation of Insulin Receptor Substrate-1 in Vascular Smooth Muscle Cells
    Hitomi, Hirofumi, Kiyomoto, Hideyasu, Nishiyama, Akira, Hara, Taiga, Moriwaki, Kumiko, Kaifu, Kumiko, Ihara, Genei, Fujita, Yoshiko, Ugawa, Toyomu, Kohno, Masakazu · 2007 · Hypertension
  20. Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
    Stefano Bianchi, Roberto Bigazzi, Vito M. Campese · 2005 · American Journal of Kidney Diseases
  21. Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns
    Kasper Rossing, Harald Mischak, Hans‐Henrik Parving, Per K Christensen, Michael Walden, Meike Hillmann, Thorsten Kaiser · 2005 · Kidney International
  22. Renin Inhibition in Hypertension
    Alan H. Gradman, Rishi Kad · 2008 · Journal of the American College of Cardiology
  23. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide
    S.G. Chrysant · 2004 · American Journal of Hypertension
  24. Microvascular complications: pathophysiology and management
    Karunakaran Vithian, Steven J. Hurel · 2010 · Clinical Medicine
  25. Review: Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19
    Gulam Rabbani, Saeyoung Nate Ahn · 2021 · International Journal of Biological Macromolecules
  26. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
    Roman‐Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, Giovambattista Capasso, Émilie Cornec-Le Gall, Olivier Devuyst, Albertien M. van Eerde, Patrick Guirchoun, Tess Harris, Ewout Jasper Hoorn et al. · 2021 · Nephrology Dialysis Transplantation
  27. Diabetic nephropathy and retinopathy
    Ali Jawa, Juanita Kcomt, Vivian Andrew Fonseca · 2004 · Medical Clinics of North America
  28. Functional expression of the renin-angiotensin system in human podocytes
    Max C. Liebau, D. Lang, Jeanne M Bohm, Nicole Endlich, Martin Johannes Bek, Ian R. Witherden, Peter William Mathieson, Moin Ahson Saleem, Hermann Pavenstädt, Karl-Georg Fischer · 2005 · American Journal of Physiology-Renal Physiology
  29. The Renin-Angiotensin System and Diabetic Nephropathy
    Susan B. Gurley, Thomas M. Coffman · 2007 · Seminars in Nephrology
  30. Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart
    Hoong Sern Lim, Robert J. MacFadyen, Gregory Y.H. Lip · 2004 · Archives of Internal Medicine
  31. The Vasculature in Prediabetes
    Wasserman, David H., Wang, Thomas J., Brown, Nancy J. · 2018 · Circulation Research
  32. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials
    Sripal Bangalore, Sunil Kumar, Jørn Wetterslev, Franz H. Messerli · 2011 · BMJ
  33. The kidney, a cardiovascular risk marker, and a new target for therapy
    Dick de Zeeuw, Hans L. Hillege, Paul E. de Jong · 2005 · Kidney International
  34. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations
    Averitt, Amelia J., Weng, Chunhua, Ryan, Patrick, Perotte, Adler · 2020 · npj Digital Medicine
  35. FGF23 and klotho at the intersection of kidney and cardiovascular disease
    Daniel L. Edmonston, Alexander Grabner, Myles Selig Wolf · 2023 · Nature Reviews Cardiology
  36. Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes
    Meg Jardine, Jun Hata, Mark Woodward, Vlado Perkovic, Toshiharu Ninomiya, Hisatomi Arima, Sophia Zoungas, Alan Cass, Anushka A Patel, Michel Marre et al. · 2012 · American Journal of Kidney Diseases
  37. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
    Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R. Hemmelgarn, Adeera Levin, Merlin C. Thomas, Christoph Wanner, B.L. Kasiske, David Collins. Wheeler, Per‐Henrik Groop et al. · 2016 · Kidney International
  38. Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers
    Roland E. Schmieder · 2005 · American Journal of Hypertension
  39. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis1
    Arthur J. Matas, Abhinav Humar, Kristen J. Gillingham, William D. Payne, Rainer W.G. Gruessner, Raja Kandaswamy, David L. Dunn, John S. Najarian, David E.R. Sutherland · 2002 · Kidney International
  40. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007
    Paola Fioretto, Maria Luiza Caramori, Michael S. Mauer · 2008 · Diabetologia
  41. Is There a Rationale for Angiotensin Blockade in the Management of Obesity Hypertension?
    Arya Mitra Sharma · 2004 · Hypertension
  42. Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment Strategy
    Peggy W G du Buf-Vereijken, A. J. W. Branten, Jack F.M. Wetzels · 2005 · American Journal of Kidney Diseases
  43. Renoprotective effects of vitamin D analogs
    Yan Chun Li · 2009 · Kidney International
  44. Antihypertensive treatment in patients with type-2 diabetes mellitus
    Alberto Zanchetti, Luis Miguel Ruilope · 2002 · Journal of Hypertension
  45. Surrogate End Points for Clinical Trials of Kidney Disease Progression
    Lesley A. Stevens, Tom Greene, Andrew S. Levey · 2006 · Clinical Journal of the American Society of Nephrology
  46. Impact of Common Medications on Serum Total Prostate-Specific Antigen Levels: Analysis of the National Health and Nutrition Examination Survey
    Steven Lee Chang, Lauren C. Harshman, Joseph C. Presti · 2010 · Journal of Clinical Oncology
  47. Hyperkalemia and Hypokalemia in CKD: Prevalence, Risk Factors, and Clinical Outcomes
    Sarah Gilligan, Kalani L. Raphael · 2017 · Advances in Chronic Kidney Disease
  48. Angiotensin Type 2 Receptor in Resistance Arteries of Type 2 Diabetic Hypertensive Patients
    Carmine Savoia, Rhian M. Touyz, Massimo Volpe, Ernesto L. Schiffrin · 2006 · Hypertension
  49. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
    Frederik Persson, Peter R Rossing, Katrine Jordan Schjoedt, Tina R. Juhl, Lise Tarnow, Coen D.A. Stehouwer, Caspar Schalkwijk, Frans Boomsma, Erik Frandsen, H.-H. Parving · 2008 · Kidney International
  50. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice
    Marpadga A. Reddy, Sumanth Putta, Linda L. Lanting, Hang Yuan, Mei Wang, Daniel Mar, Charles E. Alpers, Karol Bomsztyk, Rama D Natarajan · 2013 · Kidney International
  51. Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis
    Lesley A. Inker, Andrew S. Levey, Kruti A. Pandya, Nicholas Stoycheff, Aghogho Okparavero, Tom Greene · 2014 · American Journal of Kidney Diseases
  52. Endothelial-Podocyte Crosstalk: The Missing Link Between Endothelial Dysfunction and Albuminuria in Diabetes
    Ferhan S. Siddiqi, Andrew Advani · 2013 · Diabetes
  53. Targeting angiogenesis and lymphangiogenesis in kidney disease
    Katsuyuki Tanabe, Jun Wada, Yasufumi Sato · 2020 · Nature Reviews Nephrology
  54. Regression of Nephropathy Developed in Diabetes by (Pro)renin Receptor Blockade
    Hidena Takahashi, Atsuhiro Ichihara, Yuki Kaneshiro, Kenta Inomata, Mariyo Sakoda, Tomoko Yamashita Takemitsu, Akira Nishiyama, Hiroshi Itoh · 2007 · Journal of the American Society of Nephrology
  55. Clinical Features and Contemporary Management of Patients with Low and Preserved Ejection Fraction Heart Failure: Baseline Characteristics of Patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and Morbidity (CHARM) Programme
    John J.V. McMurray, Jan Östergren, Michael Pfeffer, Karl B Swedberg, Christopher Bull Granger, Salim Yusuf, Peter Held, Eric L. Michelson, Bertil Olofsson · 2003 · European Journal of Heart Failure
  56. Association of Kidney Disease Outcomes With Risk Factors for CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study
    Wei Peter Yang, Dawei Xie, Amanda Hyre Anderson, Marshall M. Joffe, Tom Greene, Valerie L. Teal, Chi‐yuan Hsu, Jeffrey Craig Fink, Jiang He, James Phillip Lash et al. · 2013 · American Journal of Kidney Diseases
  57. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.
    Ali Momeni, Shahrzad Shahidi, Shiva Seirafian, Shahram Taheri, Soleiman Kheiri · 2010 · Iranian Journal of Kidney Diseases
  58. Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities
    Izabela Tuleta, Nikolaos Georgios Frangogiannis · 2021 · Advanced Drug Delivery Reviews
  59. Treatment of Hypertension in Patients With Coronary Artery Disease
    Clive Rosendorff, Daniel T. Lackland, Matthew Allison, Wilbert S. Aronow, Henry R. Black, Roger Scott Blumenthal, Christopher Paul Cannon, James A. de Lemos, W.J. Elliott, Laura Findeiss et al. · 2015 · Journal of the American College of Cardiology
  60. Impact of Renin Angiotensin System Modulation on the Hyperfiltration State in Type 1 Diabetes
    Etienne B. Sochett, David Z.I. Cherney, Jacqueline R. Curtis, Maria G. Dekker, James William Scholey, Judith Miller · 2006 · Journal of the American Society of Nephrology
  61. Heart Failure With Preserved Ejection Fraction Expert Panel Report
    Kishan S. Parikh, Kavita Sharma, Mona Fiuzat, Howard K. Surks, Jyothis Thomas George, Narimon Honarpour, Christophe Depré, Patrice M. Desvigne-Nickens, Richard Nkulikiyinka, Gregory D. Lewis et al. · 2018 · JACC Heart Failure
  62. Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy
    Temitope Isaac Adelusi, Lei Du, Hao Meng, Xueyan Zhou, Xuan Qian, Apu Chowdhury, Ying Sun, Qian Lü, Xiaoxing Yin · 2020 · Biomedicine & Pharmacotherapy
  63. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
    Finnian R. Mc Causland, Brian Lee Claggett, Muthiah Vaduganathan, Akshay Suvas Desai, Pardeep S. Jhund, Rudolf A. de Boer, Kieran F. Docherty, James C. Fang, Adrian F. Hernandez, Silvio E. Inzucchi et al. · 2022 · JAMA Cardiology
  64. Development of heart failure in recent hypertension trials
    Giuliano Tocci, Sebastiano Sciarretta, Massimo Volpe · 2008 · Journal of Hypertension
  65. The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes
    Paresh Dandona, Ahmad Aljada, Ajay Chaudhuri, Arindam Bandyopadhyay · 2003 · The Journal of Clinical Endocrinology & Metabolism
  66. A Low-Sodium Diet Potentiates the Effects of Losartan in Type 2 Diabetes
    Christine A. Houlihan, Terri J. Allen, Amynta L. Baxter, Sianna Panangiotopoulos, David J. CASLEY, Mark Emmanuel Cooper, George Jerums · 2002 · Diabetes Care
  67. Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity
    Jun Mori, Vaibhav B. Patel, Tharmarajan Ramprasath, Osama Abo Alrob, Jessica DesAulniers, James William Scholey, Gary D. Lopaschuk, Gavin Y. Oudit · 2014 · American Journal of Physiology-Renal Physiology
  68. Efficacy and Safety of Abelmoschus manihot for Primary Glomerular Disease: A Prospective, Multicenter Randomized Controlled Clinical Trial
    Li Zhang, Ping Li, Changying Xing, Jiuyang Zhao, Yani He, Jianqin Wang, Xiongfei Wu, Zhangsuo Liu, Ai-ping Zhang, Hongli Lin et al. · 2014 · American Journal of Kidney Diseases
  69. Risk factors for the development of albuminuria and renal impairment in type 2 diabetes--the Swedish National Diabetes Register (NDR)
    Henri Afghahi, Jan Cederholm, Björn Eliasson, B. Zethelius, Soffia Guðbjörnsdóttir, Henrik Hadimeri, Maria K Eriksson Svensson · 2010 · Nephrology Dialysis Transplantation
  70. Obesity-hypertension: an ongoing pandemic
    Emílio Antônio Francischetti, Virginia A. Genelhu · 2007 · International Journal of Clinical Practice
  71. ACE-inhibitor use and the long-term risk of renal failure in diabetes
    Samy Suissa, T. Hutchinson, James M. Brophy, Abbas Kezouh · 2006 · Kidney International
  72. Diagnosis and management of the metabolic syndrome in obesity
    Evangelos N. Liberopoulos, Dimitri P. Mikhailidis, Moses Elisaf · 2005 · Obesity Reviews
  73. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension
    Ott, Christian, Mahfoud, Felix, Schmid, Axel, Toennes, Stefan W., Ewen, Sebastian, Ditting, Tilmann, Veelken, Roland, Ukena, Christian, Uder, Michael, Böhm, Michael et al. · 2015 · Journal of Hypertension
  74. Macrophage-derived exosomes induce inflammatory factors in endothelial cells under hypertensive conditions
    Mayuko Osada‐Oka, Masayuki Shiota, Yasukatsu Izumi, Masaki Nishiyama, Masako Tanaka, Takehiro Yamaguchi, Emi Sakurai, Katsuyuki Miura, Hiroshi Iwao · 2016 · Hypertension Research
  75. Vascular and cardiac benefits of angiotensin receptor blockers
    Ernesto L. Schiffrin · 2002 · The American Journal of Medicine
  76. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy
    Stevo Julius, Michael H. Alderman, Gareth Beevers, Björn Dahlöf, Richard B. Devereux, Janice G. Douglas, Jonathan M. Edelman, Katherine E. Harris, Sverre Erik Kjeldsen, Shawna D. Nesbitt et al. · 2004 · Journal of the American College of Cardiology
  77. Two‐dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy
    Kumar Sharma, SoHee Lee, Steven Han, Sungchun Lee, Barbara B. Francos, Peter A. McCue, Richard P. Wassell, Michael Shaw, Satish P. RamachandraRao · 2005 · PROTEOMICS
  78. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management
    Gregory Y.H. Lip, Anthony H Barnett, A W Bradbury, Francesco Paolo Cappuccio, Paramjit Singh Gill, E. A. Hughes, Chris Imray, Kate B Jolly, Kiran Patel · 2007 · Journal of Human Hypertension
  79. Association of Mild to Moderate Chronic Kidney Disease With Venous Thromboembolism
    Bakhtawar Khan Mahmoodi, Ron T. Gansevoort, Inger Anne Næss, Pamela L. Lutsey, Sigrid Kufaas Brækkan, Nic J.G.M. Veeger, Ellen Elisabeth Brodin, Karina Meijer, Yingying Sang, Kunihiro Matsushita et al. · 2012 · Circulation
  80. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes
    Dilip K. Deb, Tao Sun, Kari E. Wong, Zhongyi Zhang, Gang Ning, Yan Zhang, Juan Kong, Helen Shi, Anthony Chang, Yan Chun Li · 2010 · Kidney International
  81. Temporary Angiotensin II Blockade at the Prediabetic Stage Attenuates the Development of Renal Injury in Type 2 Diabetic Rats
    Yukiko Nagai, Li Yao, Hiroyuki Kobori, Kayoko Miyata, Yuri Ozawa, Akira Miyatake, Tokihito Yukimura, Takatomi Shokoji, Shoji Kimura, Hideyasu Kiyomoto et al. · 2005 · Journal of the American Society of Nephrology
  82. Design of Combination Angiotensin Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D)
    Linda F. Fried, William C. Duckworth, Jane Hongyuan Zhang, Theresa O’Connor, Mary T. Brophy, Nicholas Emanuele, Grant D. Huang, Peter Andrew McCullough, Paul M. Palevsky, Stephen L. Seliger et al. · 2008 · Clinical Journal of the American Society of Nephrology
  83. Kidney in Hypertension
    Thomas M. Coffman, Steven D. Crowley · 2008 · Hypertension
  84. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
    Sunil Bhandari, Natalie J. Ives, Elizabeth A. Brettell, Marie Valente, Paul Cockwell, Peter Topham, John G.F. Cleland, Arif Khwaja, Meguid El Nahas · 2015 · Nephrology Dialysis Transplantation
  85. Capítulo 1 - Conceituação, Epidemiologia e Prevenção Primária
    Marcus Vinícius Bolívar Malachias, WKSB Souza, Frida Liane Plavnik, CIS Rodrigues, AA Brandão, Mário Fritsch Neves, Luiz Aparecido Bortolotto, RJS Franco, CEP Figueiredo, PCBV Jardim et al. · 2016 · Arquivos Brasileiros de Cardiologia
  86. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure
    Karl Tryggvason, Erna E. Pettersson · 2003 · Journal of Internal Medicine
  87. Are small changes in serum creatinine an important risk factor?
    Melanie L Praught, Michael G. Shlipak · 2005 · Current Opinion in Nephrology & Hypertension
  88. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension
    Kenneth Jamerson, George L. Bakris, C. C. Wun, Björn Dahlöf, Martin P. Lefkowitz, S Manfreda, Bertram Pitt, Eric J. Velazquez, Michael A. Weber · 2004 · American Journal of Hypertension
  89. ACE Inhibitors versus AT1 Receptor Antagonists in Patients with Chronic Renal Disease
    Karl F. Hilgers, Johannes F.E. Mann · 2002 · Journal of the American Society of Nephrology
  90. Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus
    George L. Bakris · 2011 · Mayo Clinic Proceedings
  91. Targeting inflammation: New therapeutic approaches in chronic kidney disease (CKD)
    Daniela Impellizzeri, Emanuela Esposito, James Attley, Salvatore Cuzzocrea · 2014 · Pharmacological Research
  92. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
    Victor J. Dzau, Elliott Marshall Antman, Henry Richard Black, David L. Hayes, JoAnn E. Manson, Jorge Plutzky, Jeffrey J. Popma, William G. Stevenson · 2006 · Circulation
  93. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy
    Akira Nishiyama, Yoshio Konishi, Naro Ohashi, Takashi Morikawa, Maki Urushihara, Isseki Maeda, M. Hamada, Masatsugu Kishida, Hirofumi Hitomi, Nobuo Shirahashi et al. · 2010 · Nephrology Dialysis Transplantation
  94. Normoalbuminuric diabetic kidney disease
    Chao Chen, Chang Wang, Chun Hu, Yachun Han, Li Zhao, Xuejing Zhu, Li Xiao, Lin Sun · 2017 · Frontiers of Medicine
  95. Novel Insights into Diabetic Kidney Disease
    Ewelina Młynarska, Dominika Buławska, Witold Czarnik, Joanna Hajdys, Gabriela Majchrowicz, Filip Prusinowski, Magdalena Stabrawa, Jacek Rysz, Beata Franczyk · 2024 · International Journal of Molecular Sciences
  96. Tissue renin angiotensin systems
    Richard N. Ré · 2004 · Medical Clinics of North America
  97. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: A meta-analysis
    Saravanan Balamuthusamy, Lavanya Srinivasan, Meenakshi Verma, Sasikanth Adigopula, Nishant Jalandara, Suresh C. Hathiwala, Earl L. Smith III · 2008 · American Heart Journal
  98. Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
    Luca Di Lullo, Antonio Bellasi, Vincenzo Bàrbera, Domenico Russo, Luigi Russo, Biagio Raffaele Di Iorio, Mario Gennaro Cozzolino, Claudio Ronco · 2017 · Indian Heart Journal
  99. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD
    Arjun D. Sinha, Rajiv Agarwal · 2018 · Clinical Journal of the American Society of Nephrology
  100. Reversibility of established diabetic glomerulopathy by anti-TGF-β antibodies in db/db mice
    Sheldon Chen, María del Carmen Iglesias de la Cruz, Belinda Jim, Soon Won Hong, Motohide Isono, Fuad N. Ziyadeh · 2003 · Biochemical and Biophysical Research Communications